Clinical Trial Detail

NCT ID NCT01877083
Title Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Eisai Co., Ltd.
Indications

lung adenocarcinoma

Therapies

Lenvatinib

Age Groups: adult

Additional content available in CKB BOOST